Executive Intelligence

Chris Gibson

Founder

Chris Gibson is listed as a founder of Recursion Pharmaceuticals based in United States on Brel Digital’s verified company intelligence record.

Company Intelligence Official Website
In this profile

Quick Facts

  • Role Founder
  • Company Recursion Pharmaceuticals
  • Country United States
  • Industry AI in Healthcare
  • Founded 2013
  • Known For Recursion is a reference implementation of TechBio: petabyte-scale biological data generation, in-house compute, and clinical readouts…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

Chris Gibson appears in Brel Digital’s verified company_founders attribution for Recursion Pharmaceuticals based in United States in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified Recursion Pharmaceuticals profile): Salt Lake City TechBio company industrializing AI-driven drug discovery with clinical-stage assets including REC-4881 Why the company matters (verified company field): Recursion is a reference implementation of TechBio: petabyte-scale biological data generation, in-house compute, and clinical readouts that test whether AI phenotypic screening can produce registrational drug candidates — exemplified by December 2025 TUPELO data for REC-4881 in familial adenomatous polyposis. Official company website on file: https://www.recursion.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2013 Company founded

    Recursion Pharmaceuticals was founded in 2013 per the company profile source on file.

    Source
  2. 2013 Development

    2013: Recursion Pharmaceuticals founded in Salt Lake City; Chris Gibson co-founded the company from University of Utah research.

    Source
  3. 2024 Development

    November 20, 2024: Recursion completed its combination with Exscientia; Exscientia became a wholly owned subsidiary.

    Source
  4. 2025 Development

    December 8, 2025: Recursion announced positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, with 43% median polyp burden reduction at 12 weeks and durable responses at Week 25.

    Source
  5. 2026 Development

    January 1, 2026: Najat Khan, Ph.D., became chief executive officer; Chris Gibson transitioned to chair of the board, per Recursion governance disclosures.

    Source

Connected Company

Connected Products

Biotechnology

Recursion OS

Recursion OS platform combining automated experimentation, proprietary biological and chemical datasets, and AI models to discover…

View Product

Connected Reports

Connected Insights

Industry Intelligence

AI in Healthcare Open industry

Chris Gibson appears in Brel Digital’s verified company_founders attribution for Recursion Pharmaceuticals based in United States in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified Recursion Pharmaceuticals profile): Salt Lake City TechBio company industrializing AI-driven drug discovery with clinical-stage assets including REC-4881

Why the company matters (verified company field): Recursion is a reference implementation of TechBio: petabyte-scale biological data generation, in-house compute, and clinical readouts that test whether AI phenotypic screening can produce registrational drug candidates — exemplified by December 2025 TUPELO data for REC-4881 in familial adenomatous polyposis.

Official company website on file: https://www.recursion.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

Request a correction if you represent this company or believe information is inaccurate.

The AI Brief

Founder and company intelligence, weekly.

Subscribe